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We developed a microfluidics-based model to quantify cell-level
processes modulating the pathophysiology of sickle cell disease
(SCD). This in vitro model enabled quantitative investigations of
the kinetics of cell sickling, unsickling, and cell rheology. We created
short-term and long-term hypoxic conditions to simulate normal and
retarded transit scenarios in microvasculature. Using blood samples
from 25 SCD patients with sickle hemoglobin (HbS) levels varying
from 64 to 90.1%, we investigated how cell biophysical alterations
during blood flow correlated with hematological parameters, HbS
level, and hydroxyurea (HU) therapy. From these measurements, we
identified two severe cases of SCD that were also independently
validated as severe from a genotype-based disease severity clas-
sification. These results point to the potential of this method as
a diagnostic indicator of disease severity. In addition, we investi-
gated the role of cell density in the kinetics of cell sickling. We
observed an effect of HU therapy mainly in relatively dense cell
populations, and that the sickled fraction increased with cell density.
These results lend support to the possibility that the microfluidic
platform developed here offers a unique and quantitative approach
to assess the kinetic, rheological, and hematological factors involved
in vasoocclusive events associated with SCD and to develop al-
ternative diagnostic tools for disease severity to supplement other
methods. Such insights may also lead to a better understanding of
the pathogenic basis and mechanism of drug response in SCD.
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Sickle cell disease (SCD) is characterized by acute and chronicvasoocclusion that can cause pain (1), acute chest syndrome
(2), organ damage (3), stroke, and even death (4, 5). The path-
ogenic basis of “painful crisis” arising from vasoocclusion in SCD
is extremely complex (6–8). It is triggered by many factors, in-
cluding poor deformability of red blood cells (RBCs), adhesion
among multiple cell types and blood components (e.g., sickle
RBCs, endothelial cells, adherent leukocytes, and possibly plate-
lets), as well as the local microenvironment (e.g., low oxygen
concentration and acidosis). Under conditions of low oxygen
partial pressure (pO2), sickle RBCs experience intracellular
sickle hemoglobin (HbS) polymerization, thereby reducing cell
deformability (9). Such reductions in deformability can severely
impact blood flow in narrow vessels, ultimately causing a tran-
sient or persistent blockage (10). Competition between the delay
time for HbS polymerization and the RBC transit time in mi-
crocirculation is likely a key determinant of disease severity (11).
Both in vitro (12) and ex vivo (13) models reveal that HbS po-
lymerization and its effect on cellular rigidity play important
roles in causing vascular obstruction. For example, HbS poly-
merization alone could be sufficient to cause complete RBC
blockage in vasculature (12). Increases in microvascular transit
time, arising from higher rigidity, of sickle RBCs cause periph-
eral vascular resistance to blood flow (13).
The search for better means to predict painful vasoocclusion
crises has focused on a range of hematological and rheological
abnormalities. Significant correlations have been shown between
pain rates and early death in patients with sickle cell anemia (14)
and between early death and several risk factors such as fetal
hemoglobin (HbF), hematocrit, and white cell count (15). How-
ever, factors such as patient age, sex, HbF (16), intracellular HbS
polymerization (17), or fraction of dense RBCs (18) do not appear
to show a sufficiently direct correlation with the frequency and/or
severity of pain crises. Although HbF level is generally considered
important, its direct connection to disease severity is not fully
established (19, 20). Some possible links between the incidence of
painful crises and steady-state cell hydration (21) and/or deform-
ability at isotonic osmolarity have been identified (22). Such con-
nections, however, do not account for the observation that cell
deformability and the proportion of dense cells vary longitudinally
in the same patient during crisis (23). Changes have also been
reported in the biorheological characteristics of sickle RBC sus-
pension following deoxygenation (DeOxy) in an in vitro vascular
model (24).
An in vitro model with a well-defined vascular structure and
a well-controlled hypoxia condition would serve as an ideal tool
to investigate many complex pathophysiological processes in
vasoocclusion. Recent advances in microfluidics technology have
enabled us to design unique in vitro capabilities with biophysi-
cally appropriate microenvironments that mimic the geometric
features of vascular systems, thereby facilitating quantitative
characterization of DeOxy blood flow (12, 24), detection of HbS
polymerization in DeOxy liquid drops (25), and investigation of
pathologic adhesion in blood rheology (26). Several methods
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have been developed to mimic oxygen depletion whereby HbS
polymerization and subsequent cell sickling can be triggered;
they include long-term gas perfusion at low pO2 level (13, 27),
DeOxy medium exchange (25, 28), reducing agents (29–31), and
laser photodissociation of carbon monoxide (22, 32). Along with
complex in vivo models that reflect the dynamic response of
cells, an in vitro model would have the potential to predict the
conditions that would lead to vasoocclusion and to improve the
assessment of disease severity by quantifying the individual param-
eters that modulate vasoocclusion.
We designed a microfluidic platform (Fig. 1) that mimics the
rheology of microcirculation in vivo. It also characterizes the
isolated effects of cell morphologic sickling, unsickling, and al-
tered cell rheology. With this design, we explored in a systematic
and controlled manner possible correlations of these effects with
hematological parameters (e.g., %HbS), cell density, and hy-
droxyurea (HU) therapy.
Cell sickling was measured using a double-layer device with
a cell channel (5 μm high), a gas channel (100 μm high), and an in-
between polydimethylsiloxane (PDMS) film 150 μm in thickness
(Fig. 1A). The O2 concentration was controlled by exchanging gas
flow in the channel through the PDMS membrane, which is gas-
permeable (33). Although it is known (34) that the morphology of
sickled cells depends on the DeOxy rate, we observed heteroge-
neity in cell morphology at the same DeOxy rate. Sickle RBCs
typically form spiky edges and dark coarse texture due to in-
tracellular HbS polymerization, the visual identification of which
was enhanced by a band-pass filter (Fig. 1B and Movie S1). We
thus define sickled cells as those obviously distorted from their
original shape and/or texture under the Oxy state [O2 concen-
tration ∼20% (vol/vol)] to the DeOxy state (O2 concentration
<5%). This visual determination of cell sickling was further con-
firmed with an independent single-cell rheology test, where sim-
ilar trends were observed in cell sickling and single-cell capillary
obstruction (Results). The kinetics of cell sickling was quantified
by two parameters: the sickled fraction (the fraction of all RBCs
in the sample that are sickled) and the delay time of cell sickling
(the time elapsed between the initiation of DeOxy and the point
when a cell shows optically visible features of morphologic sickling).
The delay time of cell unsickling was defined as the time elapsed
between the initiation of reoxygenation (ReOxy) and the point
when the RBC fully recovered its presickle morphology in a vis-
ibly identifiable manner.
Individual-cell rheology was measured using a microfluidic
channel that consisted of periodic obstacles forming microgates
4 μm wide, 5 μm deep, and 15 μm long (Fig. 1C). The channel
dimensions were chosen to mimic the size of the smallest
capillaries in the human body (4–10 μm in diameter) (35). Cell
velocity was measured as the average velocity of individual RBCs
flowing through periodic gates under a constant differential
pressure. The obstruction fraction was determined as the ratio of
obstructed RBCs to all RBCs entering into the microgate arrays
during the DeOxy period.
Results
Kinetics of Cell Sickling and Unsickling. Kinetics of individual cell
sickling and unsickling under transient hypoxia conditions was
quantified by the delay time and maximum sickled fraction on 25
SCD patient samples: 7 patients without HU therapy (off-HU)
and 18 patients with HU therapy (on-HU) (SI Text, Patient’s HU
Status). Short-term and long-term hypoxia conditions were created
to simulate normal and retarded transit scenarios in microvascu-
lature (Fig. 2 A and B). Representative cell sickling profiles upon
changes in O2 concentration are shown (Fig. 2C). Compared with
the relatively long sickling process (>100 s for a sickled fraction
rising from zero to a saturated, maximum level), the unsickling
process after ReOxy was much faster (<20 s for a sickled fraction
reducing from the saturated level to zero), disregarding the small
discrepancy in the DeOxy and ReOxy rates (<20 s). This obser-
vation applied to all patient samples tested.
Results of the kinetics of cell sickling were plotted against the
%HbS of individual patients (Fig. 3). The delay time of sickling was
greater than 25 s for RBCs (i.e., for reaching 5% sickled fraction)
for most of the samples in the study (Fig. 3A). The delay time of
sickling for the on-HU group was significantly longer than that for
the off-HU group (P < 0.01). Within the on-HU group, the delay
times of sickling (for the 5% sickled fraction) varied from 28 to
100 s, suggesting a difference in the efficacy of HU among dif-
ferent patients. Similar trends were observed at a higher sickled
fraction (10%; Fig. 3B). Six cases showed significantly longer delay
times (>60 s) than the others, suggesting a possible beneficial
effect of HU therapy. The two cases with the shortest delay time
(less than 25 s) of cell sickling, marked by arrows (Fig. 3C), suggest
higher risk for vasoocclusion. For the sickled fraction of each
sample reaching its saturated level under the long-term DeOxy
state, delay time of cell sickling varied widely within the same
patient and among different patients. The influence of HU ther-
apy was statistically significant for the sickling process (P < 0.02;
Fig. S1A). The distribution of delay times of cell unsickling
seemed to be random among different patients, and no significant
difference was found between the on-HU and off-HU groups (P =
0.24; Fig. S1B).
Under the short-term DeOxy state, the maximum sickled
fraction for all on-HU samples was below 15%, which was sig-
nificantly lower than that for the off-HU group (P = 0.03; Fig.
3C). Within the off-HU group, the sickled fraction was highly
variable among patients, ranging from less than 10% to over
60%. The two outliers with the most severely shortened delay
time results showed consistency with the highest sickled fractions
(Fig. 3 A–C). On the other hand, during the long-term DeOxy
Fig. 1. Microfluidic platform for investigation of biophysical alterations in sickle RBCs under transient hypoxia conditions. (A) Schematic of microfluidic
device with O2 control for studying kinetics of cell sickling and unsickling. (B) Identification of cell sickling events from a microscopic image (arrows indicate
sickled RBCs). (C) Schematic of microfluidic device with capillary-inspired structures for single-cell rheology study. Note: Schematics are not drawn to scale, and
the dimensions are in microns.
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state, the maximum sickled fraction showed a strong positive
correlation with the HbS level (Pearson’s correlation coefficient,
R = 0.79, P < 0.001; Fig. 3D). The levels of sickled fractions
under short-term and long-term DeOxy states are comparable to
previous in vitro sickling studies (36, 37) under extended DeOxy
time [from 1 to 5 h of incubation under 4% O2 (36) or 2 h of
incubation under 2% O2 (37)]. The discrepancy in DeOxy time
may be due to the rapid O2 exchange in the cell suspension using
our microfluidic system rather than the static DeOxy incubation
system in the earlier studies (36, 37). The result of kinetics of cell
sickling correlating with HbF level had a relatively weaker trend in
the opposite direction from that with HbS level (e.g., R = –0.55,
P = 0.004 for the sickled fraction under the long-term DeOxy state).
Individual Sickle RBC Rheology. Individual sickle RBC rheology
was examined, at a given pressure differential and with a short-
term transient hypoxia, as a potential diagnostic indicator of risk
for vasoocclusion (Movie S2). Sickle RBCs were deformable
during the initial 12 s (O2 concentration >5%). Here deform-
ability denotes the ability of the cell to successfully traverse the
4-μm-wide microgates. When the O2 concentration was reduced
to less than 5%, the RBCs undergoing sickling were unable to
traverse the microgates, thereby causing obstruction to RBC
flow. With ReOxy, the obstructed RBCs recovered their shape
and deformability, and flow was resumed. The velocity of sickle
RBCs was then quantified as the average speed over five
microgates for the individual RBCs traveling through the peri-
odic microgates. A representative distribution of cell velocities in
response to transient hypoxia is shown (Fig. 4B). The velocity of
individual sickle RBCs varied widely in the same patient and
among different patients. Significant correlation was found be-
tween cell velocity and the mean corpuscular volume (MCV;
Pearson’s R = −0.89, P < 0.001) (SI Text, Single-Cell Rheology
and Fig. S2). The capillary obstruction ratio was defined as the
fraction of the total number of cells that were blocked at the
microgates during the DeOxy state. The sickle cell capillary
obstruction ratio, measured on six on-HU and six off-HU patient
samples, increased with HbS concentration (Fig. 4C) similar to
that seen with the sickled fraction. In general, the on-HU group
exhibited a significantly lower capillary obstruction ratio than the
off-HU group (P = 0.03). A severe case was identified with the
highest capillary obstruction ratio and is marked by an arrow in
Fig. 4C.
The Role of Cell Density. Previous studies have demonstrated that
sickle RBCs have a broad range of cell density from 1.085 to
1.146 g/mL (38–40). To quantify the effects of cell density on the
kinetics of cell sickling and unsickling, we categorized sickle
RBCs into four populations with average cell densities of 1.086 ±
0.005 g/mL (density 1), 1.095 ± 0.005 g/mL (density 2), 1.105 ±
0.005 g/mL (density 3), and >1.111 g/mL (density 4) for 20 SCD
samples from 6 off-HU patients and 14 on-HU patients. The
majority of sickle RBCs fell within density 2 and density 3 (Fig.
S3A). We noticed a significant difference in the sickling growth
curve among different density populations of individual blood
samples under both short-term and long-term DeOxy states (Fig.
S3 B and C). Results of delay time of cell sickling and sickled
fraction were examined along with cell density and the patient’s
HU status. Delay time of cell sickling decreased with cell density
(Fig. 5A), which can be rationalized by the hydration state of the
cells (41, 42). The mean delay time of cell sickling for the on-HU
cases was statistically higher than for off-HU cases (P < 0.02). A
marked extension in the delay time of cell sickling was seen for
densities 3 and 4 with HU therapy (P = 0.01 and P = 0.06, re-
spectively). The overall delay time for unsickling did not vary
significantly among densities 1–3 or between on-HU and off-HU
groups (Fig. S4A).
The maximum sickled fraction showed a strong correlation
with cell density disregarding the patient’s HU status or hypoxia
duration (Fig. 5B and Fig. S4B). This observation is consistent
with reported correlation between HbS concentration and po-
lymerization kinetics (43, 44). Under short-term hypoxia, HU
therapy significantly suppressed sickled fraction, particularly in
densities 3 and 4 (P = 0.01 and P = 0.001, respectively). The
Fig. 2. Profiles of cell sickling and unsickling under transient hypoxia conditions with 2% for the lowest O2 concentration. (A and B) Profile of short-term
transient DeOxy (O2 concentration less than 5% for ∼25 s) (A) and profile of long-term DeOxy (O2 concentration less than 5% for ∼220 s) (B). (C) Profiles of the
sickled fraction of multiple SCD samples during long-term transient DeOxy (each curve represents an individual patient sample).
Fig. 3. Kinetics of cell sickling. Delay time of cell sickling (A) for 5% sickled fraction and (B) for 10% sickled fraction. Distributions of maximum sickled
fractions under (C) short-term transient DeOxy state (O2 concentration less than 5% for ∼25 s) and (D) long-term transient DeOxy state (O2 concentration less
than 5% for ∼220 s). Arrows indicate severe cases, defined as those where sickling delay time was less than 25 s. Red circles represent on-HU and blue circles
represent off-HU. Error bars indicate standard deviations.
1424 | www.pnas.org/cgi/doi/10.1073/pnas.1424111112 Du et al.
effects of HbF fractions on density dependence of the cell sick-
ling kinetics show that the differences between the low HbF
group (%HbF <15%, n = 10) and high HbF group (%HbF
>15%, n = 10) were not as significant as those between the on-
HU and off-HU groups (Fig. S5).
The distribution of Hb types in the density-separated pop-
ulations was obtained through high performance liquid chro-
matography (HPLC). The results of 13 patient samples (5 off-
HU and 8 on-HU) with HbS levels ranging from 66.8 to 90.4%
revealed higher levels of HbS and lower levels of HbF in density 4
than other lighter-density populations (Fig. S6). This observation
is consistent with reports that dense cells have higher HbS levels
and lower HbF levels than lighter cells (45), and that dense cells
have lower HbF levels than all RBCs (46). Surprisingly, there was
no significant difference among the three lighter populations for
all four Hb types, namely HbS, HbF, HbA (adult Hb), and HbA2
(normal variant of HbA) (Fig. S6A). The trends for Hb type vs.
cell density were quite similar in both off-HU and on-HU groups
(Fig. S6 B and C). This information seems to contradict the strong
correlation of cell sickling with cell density, as it has already been
demonstrated that cell sickling is highly dependent on %HbS. To
better elucidate this result, we established two parameters to take
into account both hydration state and Hb content, including mean
intracellular HbS concentration (MCHC-S) and mean intracellular
HbF concentration (MCHC-F) (SI Text, MCHC Estimation). The
distribution of MCHC-S increased with cell density (Fig. S6D).
Density 4 had a high MCHC-S value due to the joint effects of
high %HbS and the high MCHC value.
Discussion
Shape change was found to be a reliable marker for cell sickling in
hypoxia-induced sickled human RBCs at 37 °C (36, 37), although
an earlier study argued otherwise based on experiments done at
24 °C (47). Through imaging flow cytometry, the shape change
was confirmed to be highly correlated with the existence of in-
tracellular HbS polymers identified by transmission electron mi-
croscopy (TEM) in a recent study (37). Our hypoxia assay is
expected to have a higher efficacy for identifying sickled RBCs,
because it can incorporate another visual characteristic, cell tex-
ture, in addition to changes in cell morphology. The majority
of sickled cells (density fractions 1–3) had apparent shape
change. Very few sickled cells, especially in density 4, showed
little or no apparent shape change but notable changes in cell
texture, sharing similar features to the ones at rapid DeOxy rates
by O2 reducing agents (25, 31). The rather low sickled fractions
found in Fig. 3 at relatively high %HbS, especially under the
short-term DeOxy state, is consistent with the implication that
most cells are prevented from sickling in vivo or under physio-
logically relevant conditions (10).
The kinetics of cell sickling was markedly affected by HU
therapy, including delay time of cell sickling (P < 0.01 for 5% and
10% of sickled fractions; P < 0.02 for saturated sickled fraction)
and maximum sickled ratio under the short-term hypoxia state
(P = 0.03). This analysis highlighted the beneficial effects of HU
therapy on DeOxy sickle RBCs. These results are consistent with
previous clinical reports of disease amelioration through the
stimulation of HbF synthesis (48–51). Additionally, we identified
outlier patient samples (marked by arrows in Figs. 3 A and C and
4C) that showed the most abnormal results in our assays, in-
cluding shortest delay time of cell sickling, highest sickled frac-
tion, and highest capillary obstruction ratio, all suggesting high
risk for vasoocclusion. Hematological measurements indicated
these two patient samples to be severe SCD, according to a
genotype-based disease severity classification (52). Our analysis
also indicated that HbF levels do not completely account for the
kinetics of cell sickling, including the maximum sickled fraction
(R = −0.4, P = 0.05 for short-term hypoxia state; R = −0.55, P =
0.005 for long-term hypoxia state) and the delay time of cell
sickling (R = 0.35, P = 0. 08 at a low sickled fraction, 5%). These
observations are consistent with studies indicating only partial
correlation between HbF fraction and painful crises (16, 20, 22).
The large variations in delay time of cell sickling in the on-HU
group could correlate with additional outcomes from HU ther-
apy besides HbF induction (53, 54). Therefore, our analysis could
offer a unique route to developing a supplementary tool at cellular
Fig. 4. Individual sickle RBC rheology under transient hypoxia. (A) Time sequence of RBCs traveling through capillary-inspired structures. Arrows indicate
sickled cells that are unable to pass through the microgates, thereby obstructing RBC flow. (B) Representative velocity profile of RBC flow, with each data
point representing the average speed of an individual RBC traveling through five of the periodic microgates under a pressure difference of 15 mL water in
a 60-mL Terumo plastic syringe tube (equivalent to 22.6 mm H2O). The shaded area indicates an O2 concentration lower than 5%. (C) Cell capillary obstruction
ratio as a function of %HbS. The arrow indicates a severe case with the highest capillary obstruction ratio. Error bars indicate standard deviations.
Fig. 5. Role of cell density. (A) Delay time of cell sickling and (B) sickled
fraction under the short-term DeOxy state. Error bars indicate standard
deviations.
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level, beyond current hematological assays (55), to evaluate
the response to HU and other antisickling drugs for individual SCD
patients. An example of this is found with Aes-103 (5-hydrox-
ymethylfurfural), which is currently in phase II clinical trials in SCD
patients. The sickled fraction after a long-term hypoxia in sickle
RBCs incubated with Aes-103 in vitro showed a strong correlation
with the drug concentration (SI Text, Antisickling Drug and Fig. S7).
This finding is consistent with a previous study (36).
Further analysis of sickling considered hydration state and Hb
types. There was no correlation of effective sickled fraction (sickled
fraction*) (SI Text, Effective Sickled Fraction and Fig. S8) with
MCHC-F (R = –0.17, P = 0.22) but strong correlation with
MCHC-S (R = 0.71, P < 0.001). These observations indicate that
clinical hematological information alone cannot be used to eval-
uate cell sickling events in vitro. Further analysis showed a lack
of correlation between the sickled fraction* and MCHC-S/F (by
multiplying the MCHC value with the ratio of %HbS to %HbF),
suggesting that MCHC-S is a determinant factor in cell sickling
in vitro. These results also imply that when investigating the in-
fluence of HbF, the average concentration of HbF in a cell
population is less important than the HbF content in individual
RBCs (53). This interpretation is supported by an ex vivo study
showing incomplete resistance of F cells in hypoxia-induced
sickling (56).
The mean velocity of individual sickle RBCs is an integrative
measure modulated by cell size, shape, intracellular viscosity, and
membrane deformability, and could potentially serve as a direct
indicator of the ability of cells to transit in capillaries. The op-
posing effects of elevated cell size (57) and increased membrane
deformability (58) due to HU therapy both influence cell tra-
versal through microgates. Individual-cell velocity was strongly
correlated with cell volume (R = −0.89, P < 0.001) instead
of other hematological measurements, e.g., %HbS, HCT (he-
matocrit), and MCHC. Cell shape played an important role in
transit, especially for the irreversibly sickled cells in the off-HU
cases. Additionally, we found that the velocity of deformable
cells under the DeOxy state was lower than for cells under the
Oxy state, disregarding the influences of HU therapy and
transfusion (Fig. S2). This discrepancy may be caused by the
increased intracellular viscosity from HbS polymerization and
the influence of the degree of oxygenation on HbA (59). The
improved rheological properties of sickle RBCs in vivo could
therefore stem from the elevated numbers of F cells and the
beneficial effects of HbF in cell sickling (57). Similar trends were
found in the relationship between sickled fraction and %HbS
(Fig. 3C) and between capillary obstruction and %HbS (Fig. 4C),
suggesting that morphologic sickling is likely a primary factor in
occlusion in capillaries and small vessels.
Density-dependent kinetics of cell sickling provides quantita-
tive measures of selective adhesion and selective trapping of
sickle RBCs (60) in shear flow conditions (61, 62) and in vivo
conditions (63). Our observations demonstrated that the lightest
cells (density 1) had the longest delay time of sickling and the
lowest sickled fraction. This ensured high probability in main-
taining deformability for maximum contact area for adhesion
during microcirculation, agreeing well with the adhesive dy-
namics of single sickle RBCs (64). The densest cells (density 4)
exhibited the shortest delay time for cell sickling, the highest
sickled fraction, and the longest delay time for cell unsickling,
which may contribute to quick stiffening and ready trapping.
We found that the beneficial effects of HU therapy on sickling
kinetics were more evident for the relatively dense populations,
in terms of the delay time of cell sickling (P = 0.01 and P = 0.06
for density 3 and density 4, respectively) and the maximum
sickled fraction (P = 0.01 and P = 0.001 for density 3 and density
4, respectively). These factors could serve as candidate bio-
markers to evaluate the efficacy of HU therapy and to guide the
development of new therapeutics.
Materials and Methods
Sickle RBC Samples. All studies involving human blood were approved by the
institutional review board (IRB) of National Institutes of Health (NIH), Mas-
sachusetts General Hospital (MGH), and Massachusetts Institute of Tech-
nology (MIT). Blood samples from 40 SCD patients, including 26 patients with
HU therapy (on-HU), 12 patients without HU therapy (off-HU), and 2 patients
off-HU but with transfusion (off-HU/T), were collected in EDTA anticoagulant
at NIH and MGH (using written consent forms approved by NIH and MGH
IRB, respectively) and shipped to MIT on ice and stored at 4 °C. All of the
microfluidics tests were conducted within 3 d of blood drawing. For cell
sickling/unsickling tests, we used 25 samples (18 on-HU and 7 off-HU). For
the single-cell rheology test, we used 15 samples, including 6 on-HU, 7 off-
HU, and 2 off-HU/T. For the study of cell density, we used 20 samples, in-
cluding 14 on-HU and 6 off-HU. Another 13 samples (8 on-HU and 5 off-HU)
were used for HPLC characterization. For Aes-103 testing, blood samples
from 3 on-HU and 3 off-HU patients were incubated with Aes-103 at dif-
ferent concentrations (0.5, 1, 2, and 5 mM) for 1 h at 37 °C before the in vitro
sickling test.
Sickle RBC fractionation according to cell density was performed by means
of a stepwise gradient prepared with OptiPrep solution with density adjusted
with Dulbecco’s PBS (HyClone DPBS; Thermo Scientific) based on the specific
gravity. The fractionation gradient was built up with four layers of 2.5 mL
OptiPrep-DPBS medium of densities 1.081, 1.091, 1.100, and 1.111 g/mL,
respectively. A 1-mL blood sample was washed twice with PBS at 821 × g for
5 min at 21 °C and diluted into 70∼80% hematocrit. Then, the RBC pellet was
fully suspended by gentle vortexing and layered on top of the gradient. Cell
fractionation was achieved by a 30-min centrifugation at 821 × g and 21 °C.
The four fractionated populations trapped between the interfaces of suc-
cessive layers of gradient medium and in the bottom of the tube were
carefully collected with a 1-mL pipette tip and washed with 5 mL PBS buffer
twice to remove gradient residue. The four fractions, density 1–4, have mean
densities of 1.086 ± 0.005 g/mL, 1.095 ± 0.005 g/mL, 1.105 ± 0.005 g/mL, and
>1.111 g/mL, respectively. Fractionated sickle RBCs were then suspended
with RPMI-1640 containing 1% (wt/vol) BSA (Sigma-Aldrich) and stored at
4 °C until shortly before use to avoid metabolic depletion. BSA was used to
maintain the cellular livability and prevent cell adhesion to the interior
surfaces of microfluidic devices.
Microfluidic Platform. Microfluidic devices were designed and fabricated
using polydimethylsiloxane casting protocols and bonded to microscope
slides. The masters of PDMS channels were fabricated with silicon wafers
using standard photolithography techniques and followed with 2-h sur-
face passivation using fluorinated silane vapor [(tridecafluoro-1,1,2,2-
tetrahydrooctyl)-1-trichlorosilane; T2492-KG; United Chemical Technologies].
O2 concentration in the cell channel was controlled by the gas flow in the
gas channel. The transient hypoxia condition was created by switching
between two gas mixtures, including a gas mixture of 5% CO2, 20% O2
with N2 balance for an initial oxygenation and reoxygenation and a gas
mixture of 5% CO2, 2% O2 with N2 balance for deoxygenation. Two res-
ervoirs (1.5 mm in diameter and 2 mm deep) for cell buffer exchange were
fabricated 1.2 mm away from the obstacles and connected to the external
hydraulic columns via flexible Tygon microbore tubing (0.020 inch i.d. ×
0.060 inch o.d.). Before the rheology test, the microfluidic devices were
degassed for at least 15 min before filling with working medium to im-
prove wetting and prevent air bubble trapping.
Experimental Conditions. Experiments were performed on a Zeiss Axiovert 200
inverted microscope using a halogen source (100 W). Microfluidic devices
were enclosed in a heating incubator (ibidi heating system) with temperature
maintained at 37 °C for both cell sickling and rheology measurements. The
temperature state of the cell buffer within the microfluidic channel was
calibrated with a thermocouple considering the mass exchange (gas and cell
buffer) before the experiment. Images of RBCs were enhanced with a 414/
446-nm band-pass filter (Semrock). Local O2 concentration in the cell channel
was characterized offline using Tris(4,7-diphenyl-1,10-phenanthroline)
ruthenium (II) dichloride complex [Ru(dpp)3Cl2; Sigma-Aldrich], the fluores-
cence of which is strongly reduced by molecular O2 due to dynamic
quenching. Because Ru(dpp)3Cl2 is water-insoluble, it was dissolved in
acetone-RPMI (volume ratio of 1:2) at 0.8 mg/mL and injected into the cell
channel. Luminescence was measured at an emission wavelength of 488 nm.
Short-term and long-term hypoxia conditions held the durations of the
DeOxy state (O2 concentration <5%) at about 25 and 220 s, respectively. The
division of 5% was selected because sickle RBCs start to sickle when O2 is
lower than this point.
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HPLC. The relative proportions of HbS, HbF, HbA, and HbA2 of density-
separated cell populations were obtained via HPLC performed at Brigham
and Women’s Hospital.
Statistical Study. All data are expressed as mean ± SD. Statistical analyses
were performed with OriginPro 8 (OriginLab). A two-sample t test between
measurements of samples from on-HU patients and off-HU patients was
used to generate the P values with equal variance not assumed. Correlation
analyses between the biophysical measurements and the hematological
values were performed using Pearson’s correlation.
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